Interference with CHD1L inhibits the malignant progression and enhances cisplatin sensitivity of ovarian cancer cells by binding PLK1 - Qiao, Kun; Guan, Yuanxiazi; Xing, Wenjing (Journal of ovarian research, 2025)
Keywords: Animals; Antineoplastic Agents - pharmacology; Apoptosis; Apoptosis - drug effects; Cancer; Cell cycle arrest; Cell Cycle Proteins - genetics; Cell Cycle Proteins - metabolism; Cell Line, Tumor; Cell Movement - drug effects; Cell Proliferation - drug effects; CHD1L; Cisplatin; Cisplatin - pharmacology; Cisplatin - therapeutic use; Development and progression; Disease Progression; DNA Helicases - genetics; DNA Helicases - metabolism; DNA-Binding Proteins - genetics; DNA-Binding Proteins - metabolism; Dosage and administration; Drug Resistance, Neoplasm - genetics; Drug therapy; Female; Genetic aspects; Health aspects; Humans; Mice; Mice, Nude; Oncogenes; Oncology, Experimental; Ovarian cancer; Ovarian Neoplasms - drug therapy; Ovarian Neoplasms - genetics; Ovarian Neoplasms - metabolism; Ovarian Neoplasms - pathology; Physiological aspects; PLK1; Polo-Like Kinase 1; Proliferation; Protein kinases; Protein Serine-Threonine Kinases - genetics; Protein Serine-Threonine Kinases - metabolism; Proto-Oncogene Proteins - genetics; Proto-Oncogene Proteins - metabolism; Xenograft Model Antitumor Assays; China; PLK1; Cell cycle arrest; CHD1L; Proliferation; Cisplatin sensitivity; Apoptosis; Ovarian cancer